AKLRD’s business model is led by a small group of executives accessing expert opinion to guide product development.

Members of the Scientific and Clinical advisory boards are recognised experts in their field and used extensively to guide preparation for first in human studies.

Key Advisors:


Preclinical: Prof. Frank Bonner
Former Director of Science & Technology, Huntingdon Life Sciences. Former President of British Toxicology Society


Manufacturing: John McCrerie
Former Technical Director of Becpharm Limited; Senior Manager and International QA Director Wellcome Glaxo


AKL4 (aka APPA) Collaborators:

Dr Andy Cross, University of Liverpool, Research Associate Musculoskeletal Biology

Professor Ian Clark, University of East Anglia, Musculoskeletal Biology

Dr Sonya Glasson, ex senior scientist Pfizer OA animal modelling


AKL1 (aka TAKL) Collaborators:

Professor Bert van den Berg, University of Utrecht, Pharmaceutical Sciences

Dr. Kees Beukelman, University of Utrecht, Pharmaceutical Sciences

Dr Chris Jones, University of Leicester, Division of Chemical Pathology

Professor Mike Thomas, University of Southampton, Primary Care Research

Dr Daryl Freeman, specialist Respiratory and Research GP